Fig. 7. The map kinase pathway is involved in the generation of SCL-expressing cells. (A) ES cells were differentiated for three days in serum replacement with BMP4. VEGF₁₆₅ was added at day 3 with DMSO, U0124 or U0126 (MKK1-specific inhibitor). EBs were harvested at day 5 and subjected to FACS analysis for FLK⁺ and SCL⁺ cell generation. Numbers in a given box indicate the percentage of FLK1⁺CD4^– (lower right), FLK⁺CD4⁺ (upper right) and FLK1^–CD4⁺ (upper left) cells. (B) Results from three independent experiments are shown as a percentage of U0124 control. Error bars indicate s.e.m.